A possible side effect of serotonin-enhancing drugs is the serotonin syndrome, which can be lethal. Here we examined possible hypersensitivity to two such drugs, the serotonin precursor 5-hydroxy-L-tryptophan (5-HTP) and the atypical opioid tramadol, in mice lacking the genes for both monoamine oxidase A (MAOA) and MAOB. MAOA/B-knockout (KO) mice displayed baseline serotonin syndrome behaviors, and these behavioral responses were highly exaggerated following 5-HTP or tramadol versus baseline and wild-type (WT) littermates. Compared with MAOA/B-WT mice, baseline tissue serotonin levels were increased B2.6-3.9-fold in MAOA/B-KO mice. Following 5-HTP, serotonin levels were further increased B4.5-6.2-fold in MAOA/B-KO mice. These exaggerated responses are in line with the exaggerated responses following serotonin-enhancing drugs that we previously observed in mice lacking the serotonin transporter (SERT). These findings provide a second genetic mouse model suggestive of possible human vulnerability to the serotonin syndrome in individuals with lesser-expressing MAO or SERT polymorphisms that confer serotonergic system changes. and MAO, respectively, the two major mechanisms which maintain serotonin homeostasis. The blockade of SERT or MAO results in increased serotonin levels in the synapse. One possible and potentially lethal side effect of SRIs, MAOIs and other compounds is the serotonin syndrome, which typically results following ingestion of two or more serotonin-enhancing drugs.
INTRODUCTION
Two major classes of antidepressant medications are the serotonin reuptake inhibitors (SRIs) and the monoamine oxidase inhibitors (MAOIs). SRIs and MAOIs inhibit the serotonin transporter (SERT) and MAO, respectively, the two major mechanisms which maintain serotonin homeostasis. The blockade of SERT or MAO results in increased serotonin levels in the synapse. One possible and potentially lethal side effect of SRIs, MAOIs and other compounds is the serotonin syndrome, which typically results following ingestion of two or more serotonin-enhancing drugs. 1, 2 Numerous recent case studies also point to the atypical opioid tramadol as a causative drug in the development of the serotonin syndrome. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In addition to effects on the opioid and noradrenergic systems, tramadol affects the reuptake and release of serotonin [13] [14] [15] and significantly increases extracellular serotonin levels. 16, 17 In the rodent model of the serotonin syndrome, administration of two or more serotonin-enhancing drugs such as SRIs, MAOIs and the serotonin precursor 5-hydroxy-L-tryptophan (5-HTP) induce a cluster of behaviors including head weaving, forepaw treading, hind-limb abduction, low body posture, backward movement, Straub tail and tremor. [18] [19] [20] [21] As mentioned, MAO has a major role in maintaining homeostatic levels of serotonin. There are two MAO isoenzymes: MAOA preferentially breaks down serotonin and norepinephrine, whereas MAOB breaks down phenylethylamine and benzylamine, and both MAOA and MAOB can break down dopamine. [22] [23] [24] Mice lacking the MAOA and/or the MAOB gene have baseline alterations in the serotonin system. Mice lacking only MAOA have increased levels of tissue serotonin 25 and extracellular serotonin, 26 and decreased levels of serotonin's major metabolite 5-hydroxyindoleacetic acid (5-HIAA) 25 and SERT binding and function. [26] [27] [28] Mice lacking only MAOB have no changes in serotonin or 5-HIAA levels, but evidence large increases in b-phenylethylamine. 29 Mice lacking both MAOA and MAOB (MAOA/B-knockout (KO) mice) have a double gene deletion which resulted from a spontaneous mutation leading to a complete loss of MAOA function in mice already lacking MAOB. 30 Interestingly, MAOA/B-KO mice show much larger changes in the serotonin system, with greater than 8-fold increases in serotonin and 200-fold decreases in 5-HIAA in whole-brain tissue compared with wild-type (WT) mice. 30 In addition to MAO, SERT also has a major role in maintaining serotonergic homeostasis, and mice with decreased or absent SERT also have major alterations in their serotonergic systems at baseline, including increased extracellular serotonin levels. 31, 32 We previously showed that SERT-KO mice display increased baseline levels of serotonin syndrome behaviors, 19, 33, 34 in addition to further exaggerated behavioral responses following the MAOA/B inhibitor tranylcypromine, 19 5-HTP 18, 32, 35 and the atypical opioids tramadol and meperidine, 33 each when administered alone. In the current studies, we determined the behavioral and neurochemical effects of serotonin-enhancing drugs in MAOA/B-KO mice. Specifically, we assessed serotonin syndrome behaviors at baseline and following either 5-HTP or tramadol administration in MAOA/B-KO and -WT mice. Further, we measured tissue levels of serotonin, 5-HIAA and serotonin turnover rates (5-HIAA/serotonin) in brain stem, frontal cortex, hippocampus, hypothalamus and 1 striatum from MAOA/B-KO and -WT mice at baseline and following administration of the serotonin precursor 5-HTP. The findings from the current studies are important, as they further support the use of genetic mouse models of likely genetic vulnerability to the development of the serotonin syndrome in individuals with lesserexpressing functional variants in SERT and/or variants in MAO which confer changes in MAO levels and activity. 
MATERIALS AND METHODS

General procedure
On test days, animals were moved to the testing room in their home cage 1 h prior to testing to allow for habituation to the environment. All experiments were carried out between 1000 and 1300 hours.
Serotonin syndrome behaviors
Animals were placed in a large Plexiglass cylinder and after 15 min of habituation were administered 5-HTP (80 mg kg À 1 ) 18, 19 or its vehicle in the first experiment and tramadol (60 mg kg À 1 ) 33 or its vehicle in the second experiment. Behavioral assessments were made based on previous methods. 18, 19, 33 Specifically, behaviors associated with the rodent serotonin syndrome were recorded for five 1-min periods at 5-min intervals starting 5 min after drug administration. The following behaviors were recorded: (A) intermittent behaviors: head weaving, forepaw treading and backward movement (scale of 0-4; 0 ¼ absent, 1 ¼ present once, 2 ¼ present several times (2-3 times), 3 ¼ present frequently (4-6 times) and 4 ¼ present continuously (46 times)) and (B) continuous behaviors: hind-limb abduction, Straub tail, tremor and low body posture (scale of 0-4; 0 ¼ absent, 1 ¼ perceptible, 2 ¼ weak, 3 ¼ medium and 4 ¼ maximal). Overall serotonin syndrome scores were calculated for each 5-min assessment, consisting of the sum of scores for all intermittent and continuous behaviors. 19, 36 Behavioral assessments were performed by observers blind to both the genotype of the mice and the drug condition.
Analysis of brain region monoamines and metabolites
In a separate cohort of mice, 30 min following administration of 5-HTP (80 mg kg À 1 ) 18 or its vehicle, MAOA/B-WT and -KO mice were killed via cervical dislocation. Brains were removed immediately and dissected on a glass-plate set in ice as previously described, 37 and were stored at À 801C before high-performance liquid chromatography (HPLC). HPLC analysis using electrochemical detection assessing concentrations of monoamines and their metabolites was performed as previously described. 38 The system was calibrated using 5-hydroxyindole-3-acetic acid (dicyclohexyl ammonium salt) (molecular weight ¼ 191), 5-hydroxytryptamine HCl (molecular weight ¼ 176) and the internal standard No-methyl-5-hydroxytryptamine oxalate salt (molecular weight ¼ 280).
Statistical analyses
For each experiment, data were analyzed using t-tests or two-way (genotype Â drug condition) analyses of variance. Significant interactions were followed by post-hoc comparisons between genotypes or between drug conditions using t-tests or Tukey HSD pairwise comparisons. Significance was based on Po0.05.
RESULTS
Serotonin syndrome behaviors
In an initial examination of baseline serotonin syndrome behaviors, overall serotonin syndrome behaviors were increased in MAOA/B-KO mice (7.11 ± 1.07) compared with MAOA/B-WT mice (3.50±0. 48 Table 1 for statistical analyses.
5-HIAA levels. In all five brain areas measured, 5-HIAA levels in MAOA/B-KO mice were nearly undetectable both at baseline and following 5-HTP, and were thus significantly decreased compared with MAOA/B-WT mice (Figures 3a-e) . 5-HTP significantly increased 5-HIAA levels in MAOA/B-WT mice, with B8.7-14.5-fold increases compared with baseline, with no effect in MAOA/B-KO mice. See Table 1 for statistical analyses.
Serotonin turnover (5-HIAA/serotonin). In all five brain areas assessed, serotonin turnover rates were nearly undetectable in MAOA/B-KO mice at baseline and following 5-HTP, with no significant differences between these two groups ( Table 2) . 5-HTP significantly increased serotonin turnover rates in MAOA/B-WT mice, with B2.8-4.9-fold increases compared with baseline, with no effect in MAOA/B-KO mice.
DISCUSSION
Here we report enhanced serotonin syndrome behaviors at baseline and following administration of the serotonin precursor 5-HTP and the atypical opioid tramadol in MAOA/B-KO mice. Further, 5-HTP administration resulted in enhanced increases in serotonin in MAOA/B-KO mice. These findings are consistent with our previous reports in SERT-KO mice. 18, 19, 33 The current findings are important, as they provide further support for the use of genetically modified animal models for the evaluation of possible human genetic vulnerability to developing the serotonin syndrome in individuals taking serotonin-enhancing drugs.
At baseline, MAOA/B-KO mice displayed increased serotonin syndrome behaviors compared with MAOA/B-WT mice, similar to our previous findings in SERT-KO mice. 19, 33, 34 The current findings in MAOA/B double KO mice are in line with a previous report in MAOA-KO mice, in which baseline behaviors resembling the serotonin syndrome were observed in pups (but not in adult mice), although specific quantification of these behaviors was not reported. 25, 39 These behaviors in MAOA-KO mice appear to be related to elevated serotonin levels, as treatment with the serotonin synthesis inhibitor parachlorophenylalanine (but not the catecheholamine synthesis inhibitor alpha-methylparatyrosine) reversed all of these baseline behaviors. 25 In addition to these baseline behaviors, MAOA/B-KO mice displayed exaggerated serotonin syndrome behaviors following administration of the serotonin precursor 5-HTP or the atypical opioid tramadol. These findings are also similar to those previously reported in SERT-KO mice. 18, 19, 33, 35 In one previous study with MAOA-KO mice, the serotonin releaser D-fenfluramine induced serotonin syndrome behaviors, with a significantly lower ED 50 in MAOA-KO mice compared with WT mice. 40 Further, MAOA-KO mice evidenced B4-fold enhanced increases in extracellular serotonin concentrations compared with WT mice following the SRI citalopram, 26, 27 which might contribute to the current behavioral findings with tramadol, which also blocks SERT 14 and increases serotonin levels. 16, 17 It is interesting to note that the dopamine transporter (DAT) and the norepinephrine transporter have been shown to promiscuously take up serotonin in MAOA-KO mice, 39 likely a compensatory mechanism for prolonged enhanced levels of extracellular serotonin. 26 DAT similarly takes up serotonin in SERT-KO mice, 41 also likely to compensate for long-term elevations in extracellular serotonin. 42 We previously showed that pharmacological blockade of DAT with the selective DAT blocker GBR 12909 further enhanced 5-HTP-induced serotonin syndrome behaviors in SERT-KO mice. 18 However, that the above-mentioned baseline 'serotonin syndromelike' behaviors observed in MAOA-KO mice were still present in mice lacking both MAOA and DAT (with no such behaviors in mice lacking only DAT) 39 suggests that the uptake of serotonin by DAT was not a factor in these baseline behaviors.
The only previous study in double MAOA/B-KO mice to date found increased baseline levels of tissue serotonin and decreased levels of 5-HIAA in whole brain compared with WT mice, levels Abbreviations: ANOVA, analysis of variance; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HTP, 5-hydroxy-L-tryptophan; KO, knockout; MAO, monoamine oxidase; WT, wild-type.
which were higher than those observed in MAOA-KO mice. 30 Here we report that baseline levels of tissue serotonin were increased B2.6-3.9-fold compared with MAOA/B-WT mice, and levels of 5-HIAA and serotonin turnover rates were markedly reduced in MAOA/B-KO mice compared with MAOA/B-WT mice consistently across all five brain areas assessed (brain stem, frontal cortex, hippocampus, hypothalamus and striatum).
Following administration of 5-HTP, tissue serotonin levels were increased B2.1-3.5-fold in MAOA/B-WT mice compared with baseline, whereas tissue serotonin levels were more markedly increased B3.2-6.3-fold in MAOA/B-KO mice compared with baseline. The enhanced increases in tissue serotonin levels following 5-HTP, which has also been shown to dose-dependently increase extracellular serotonin levels, 43 could likely form a basis for the enhanced behavioral response observed in MAOA/B-KO mice, similar to findings in SERT-KO mice, 18 especially as these behaviors were absent in MAOA-KO mice treated with the serotonin synthesis inhibitor parachlorophenylalanine. 25 Furthermore, as mentioned, increases in extracellular serotonin following the SRI citalopram were B4-fold higher in MAOA-KO mice than that observed in WT mice. 26 It is also of note that the highest increases in tissue serotonin levels following 5-HTP in MAOA/B-KO (B6.3-fold) and SERT-KO mice (B11.7-fold 18 ) were in the striatum, an important locomotor-related brain area that may contribute to these behavioral responses.
In humans, there are several genetic variations in MAO, ranging from an MAOA promotor region variable number tandem repeat (VNTR) polymorphism, the length of which affects MAO function (reviewed in D'Souza and Craig 44 ) , to rare deletions of genes for both MAOA and MAOB, leading to a complete loss of MAO function like that found in our mice. [45] [46] [47] [48] The VNTR polymorphism consists of a 30-bp repeat sequence present in 2, 3, 3.5, 4 or 5 copies located upstream of the MAOA-coding region. 49, 50 Regarding the frequency of these polymorphisms, one study reported that the most frequent of these variations were the 3-and 4-repeat alleles in a population of 2156 individuals, and reported substantial differences in allele frequency across different racial/ethnic groups, 50 whereas the 2-, 3.5-and 5-repeat alleles are uncommon. [49] [50] [51] Similar to MAO-KO mice, loss of MAOA and/ or MAOB function in humans also results in elevated serotonin levels and decreased 5-HIAA levels, and has behavioral consequences. 44, 45, 52 For example, alterations in human MAO genes have been associated with impulsive and aggressive behavior, 53 Norrie disease 47 and several psychiatric disorders. 54 As a specific example, the MAOA VNTR has been associated with impulsive/ antisocial behavior, [55] [56] [57] [58] [59] autism, 60, 61 affective disorders, 49, 62, 63 substance dependence 57 and posttraumatic stress disorder. 64 The human serotonin syndrome follows ingestion of serotoninenhancing drugs, even when taken weeks apart. This potentially lethal side effect is associated with neuromuscular hyperactivity (for example, tremor and myoclonus), autonomic hyperactivity (for example, fever) and altered mental status. 21, 65 Drugs implicated in the serotonin syndrome include members of several classes of drugs, including SRIs, MAOIs (including reversible MAOIs like moclobemide) and atypical opioids such as tramadol (reviewed in Gillman 5 ). More recently, other compounds have come into question as putative serotonin syndrome-causing agents, including the triptans used to treat migraine, 66 over-the-counter and other herbal remedies such as St. John's wort (hypericum), 66 methylene blue with medical therapeutic and staining uses (reviewed in Bonetto et al.
67
) and the antibiotic linezolid, which has MAO-inhibiting properties. 68 In fact, the US Food and Drug Administration recently issued a warning regarding possible serotonin syndrome following use of linezolid or methylene blue. 69 It would be of high interest to examine the serotonin syndrome-associated responses following administration of these compounds in our genetic mouse models, based on a genetic deficiency of MAOA and/or B or SERT in combination with environmental exposure to pharmacological agents available over-the-counter or by prescription. These investigations could provide further evidence for potentially important implications for individuals with functional alterations in MAO or SERT taking such medications.
In conclusion, MAOA/B-KO mice had highly exaggerated neurochemical and serotonin syndrome behavioral responses to the serotonin precursor 5-HTP and the atypical opioid tramadol. These findings suggest that individuals with polymorphisms in MAO genes, which result in altered MAO function, may be at increased risk for developing the serotonin syndrome when taking serotonin-enhancing drugs such as tramadol. Numerous case studies implicate tramadol in the serotonin syndrome, in particular when taken in combination with serotonergic antidepressant medications. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Importantly, recent studies show that tramadol and other serotonin-enhancing drugs are frequently co-prescribed 70 and were the most frequent fatal drug combinations in a recent examination of drug-associated fatalities in Victoria, Australia, from 2002 to 2008. 2 The current findings in MAOA/B-KO mice, together with our previous studies in SERT-KO mice, may have implications for pharmacogenomics and personalized medicine, as individuals with functional alterations in SERT [71] [72] [73] and/or MAO (see above) may be at enhanced genetic risk for developing the serotonin syndrome and other toxic side effects when taking serotoninenhancing drugs. These findings also support the use and importance of genetic animal models to explore possible human vulnerability to drug side effects.
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